ACTRN12605000683639
Completed
Phase 3
se of exhaled nitric oxide levels in predicting response to oral steroids in patients with COPD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Chronic obstructive pulmonary disease (COPD)
- Sponsor
- Health Research Council of New Zealand
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with COPDFEV1 \<70% predicted, FEV1/FVC ratio \<70%Smoker or ex\-smoker of at least 20 pack years.
Exclusion Criteria
- •Acute exacerbation within the last 3 months, patients receiving long\-term oxygen treatment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical Application of exhaled Nitric Oxide measurements in PrimarY careAsthmaRespiratory - AsthmaACTRN12605000354684niversity of Otago200
Unknown
Not Applicable
The Value of FeNO in Predicting Airway Eosinophilic InflammationBiomarkersAirway InflammationNCT04885738The First Affiliated Hospital of Guangzhou Medical University2,052
Completed
Not Applicable
Exhaled Nitric Oxide : Biomarker of Acute Respiratory Distress SyndromeARDS, HumanNitric OxydeNCT06250348University Hospital, Grenoble20
Completed
Not Applicable
Phase II Evaluation of Exhaled Nitric Oxide (NO)Lung CancerNCT01392144M.D. Anderson Cancer Center36
Completed
Not Applicable
Can monitoring exhaled nitric oxide levels in outpatients improve the management of children with asthma?AsthmaRespiratoryISRCTN50872816niversity of Southampton (UK)93